« Previous
Next »
American Heart Journal
Volume 154, Issue 1
, Pages
3-11
, July 2007
Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs
To access this article, please choose from the options below
Disclosures: Dr Steinhubl received research support from and served as a consultant for Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company and served as a consultant for AstraZeneca. Doctor Berger received consulting and lecture fees from Bristol-Myers Squibb, Sanofi-Aventis, Johnson & Johnson, Genentech, Guilford, Arginox, Schering-Plough, and Boston Scientific and is the medical director and owns equity in Lumen. Doctor Kastrati received lecture fees from Bristol-Myers Squibb, Lilly, and Sanofi-Aventis.
Disclosures: Financial and editorial support for this publication has been provided by Sanofi-Aventis US Inc.
PII: S0002-8703(07)00287-6
doi: 10.1016/j.ahj.2007.04.009
« Previous
Next »
American Heart Journal
Volume 154, Issue 1
, Pages
3-11
, July 2007
